MX2018004112A - Terapia de combinacion racional para el tratamiento de cancer. - Google Patents
Terapia de combinacion racional para el tratamiento de cancer.Info
- Publication number
- MX2018004112A MX2018004112A MX2018004112A MX2018004112A MX2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A MX 2018004112 A MX2018004112 A MX 2018004112A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- agents
- combination therapy
- rational combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La descripción proporciona métodos de uso de inhibidores de proteínas chaperonas, tales como inhibidores de HSP90, en combinación con agentes que aumentan el estrés proteotóxico en células tumorales o agentes que inducen una renovación bioquímica de la chaperona. Los agentes proteotóxicos se administran antes de la administración de las proteínas chaperonas para lograr actividad sinérgica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562237470P | 2015-10-05 | 2015-10-05 | |
PCT/US2016/055594 WO2017062520A1 (en) | 2015-10-05 | 2016-10-05 | Rational combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018004112A true MX2018004112A (es) | 2018-06-20 |
Family
ID=57145064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004112A MX2018004112A (es) | 2015-10-05 | 2016-10-05 | Terapia de combinacion racional para el tratamiento de cancer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180280397A1 (es) |
EP (1) | EP3359196B1 (es) |
JP (1) | JP7132848B2 (es) |
KR (1) | KR20180058824A (es) |
CN (1) | CN108472376A (es) |
AU (1) | AU2016336351A1 (es) |
BR (1) | BR112018006572A2 (es) |
CA (1) | CA3000851A1 (es) |
EA (1) | EA201890623A1 (es) |
IL (1) | IL258494A (es) |
MA (1) | MA47474A (es) |
MX (1) | MX2018004112A (es) |
TW (1) | TW201722422A (es) |
WO (1) | WO2017062520A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016014758A8 (pt) | 2013-12-23 | 2020-06-02 | Memorial Sloan Kettering Cancer Center | composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto |
CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
CN112641949A (zh) * | 2021-01-11 | 2021-04-13 | 深圳市人民医院(深圳市呼吸疾病研究所) | 一种含有pi3k抑制剂的药物组合物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030065502A (ko) | 2000-11-02 | 2003-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법 |
US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
DK2034839T3 (en) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Res | TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90 |
KR101906146B1 (ko) | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
CA2776308C (en) | 2009-10-07 | 2020-01-28 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
KR101984480B1 (ko) | 2011-04-05 | 2019-05-31 | 슬로안-케테링인스티튜트퍼캔서리서치 | Hsp90 억제제 |
JP6266506B2 (ja) | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Hsp90阻害物質 |
KR102025142B1 (ko) | 2011-07-08 | 2019-09-26 | 슬로안-케테링인스티튜트퍼캔서리서치 | 표지된 hsp90 억제제의 용도 |
AU2014306417C1 (en) | 2013-08-16 | 2019-07-25 | Memorial Sloan-Kettering Cancer Center | Selective Grp94 inhibitors and uses thereof |
ES2774975T3 (es) | 2014-05-13 | 2020-07-23 | Memorial Sloan Kettering Cancer Center | Moduladores de hsp70 y métodos para fabricar y utilizar el mismo |
-
2016
- 2016-10-05 WO PCT/US2016/055594 patent/WO2017062520A1/en active Application Filing
- 2016-10-05 CA CA3000851A patent/CA3000851A1/en not_active Abandoned
- 2016-10-05 TW TW105132272A patent/TW201722422A/zh unknown
- 2016-10-05 US US15/765,980 patent/US20180280397A1/en not_active Abandoned
- 2016-10-05 KR KR1020187012285A patent/KR20180058824A/ko unknown
- 2016-10-05 AU AU2016336351A patent/AU2016336351A1/en not_active Abandoned
- 2016-10-05 MA MA047474A patent/MA47474A/fr unknown
- 2016-10-05 MX MX2018004112A patent/MX2018004112A/es unknown
- 2016-10-05 JP JP2018536719A patent/JP7132848B2/ja active Active
- 2016-10-05 CN CN201680069308.9A patent/CN108472376A/zh active Pending
- 2016-10-05 EA EA201890623A patent/EA201890623A1/ru unknown
- 2016-10-05 BR BR112018006572A patent/BR112018006572A2/pt not_active Application Discontinuation
- 2016-10-05 EP EP16782374.9A patent/EP3359196B1/en active Active
-
2018
- 2018-04-04 IL IL258494A patent/IL258494A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180058824A (ko) | 2018-06-01 |
CA3000851A1 (en) | 2017-04-13 |
EA201890623A1 (ru) | 2018-09-28 |
JP2018537519A (ja) | 2018-12-20 |
JP7132848B2 (ja) | 2022-09-07 |
AU2016336351A1 (en) | 2018-05-10 |
MA47474A (fr) | 2019-12-25 |
TW201722422A (zh) | 2017-07-01 |
EP3359196A1 (en) | 2018-08-15 |
EP3359196B1 (en) | 2022-03-16 |
CN108472376A (zh) | 2018-08-31 |
BR112018006572A2 (pt) | 2018-10-09 |
IL258494A (en) | 2018-05-31 |
WO2017062520A1 (en) | 2017-04-13 |
US20180280397A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501818A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MA39906A (fr) | Polythérapies pour le traitement du cancer | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
WO2016025635A3 (en) | Combination therapy for treating cancer | |
MX2017007321A (es) | Terapias de combinacion. | |
UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
WO2016043874A3 (en) | Combination therapy for treating cancer | |
BR112017000556A2 (pt) | terapia de combinação para câncer | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
BR112017018198A2 (pt) | inibição da atividade de olig2 | |
MX2017015532A (es) | Terapia de combinacion pac-1. | |
PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. |